\-\ Texto\\:\\ \ \(0\)\
\-\ labs\\:\ \(4\)\
\-\ pth\\ \\=\\ 85\\.1\\ \\ \\(normal\\ range\\:\\ \\ 13\\-65\\)\ \(0\)\
\-\ ca\\+\\+\\ \\=\\ 10\\.9\\ \\ \\(normal\\ range\\:\\ \\ 8\\.4\\-10\\.2\\)\ \(0\)\
\-\ vit\\ d\\ \\=\\ normal\ \(0\)\
\-\ surgical\\ excision\\,\\ follow\\-up\\ labs\\ to\\ ensure\\ normalization\ \(0\)\
\-\ early\\ images\\:\\ \\ small\\ \\ focus\\ of\\ increased\\ radiotracer\\ accumulation\\ at\\ the\\ left\\ lower\\ thyroid\\ region\\,\\ which\\ appears\\ extraglandular\ \(0\)\
\-\ late\\ images\\:\\ \\ appropriate\\ thyroid\\ washout\\ with\\ the\\ focus\\ of\\ increased\\ radiotracer\\ accumulation\\ at\\ the\\ left\\ lower\\ thyroid\\ region\\,\\ now\\ more\\ evident\ \(0\)\
\-\ parathyroid\\ adenoma\\:\\ \\ probable\\ \\-\\ pending\\ surgical\\ confirmation\ \(0\)\
\-\ 1\\)\\ \\ parathyroid\\ adenoma\ \(0\)\
\-\ 2\\)\\ \\ less\\ likely\\ an\\ exophytic\\ thyroid\\ adenoma\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ 3\\)\\ \\ thyroidal\\ or\\ extrathyroidal\\ malignancy\\,\\ lymphoma\\,\\ etc\ \(0\)\
\-\ 56\\ y\\/o\\ male\\ with\\ recurrent\\ kidney\\ stones\\ and\\ elevated\\ pth\\.\ \(0\)\
\-\ early\\ images\\ \\ \\(\\‚\\Ä\\úthyroid\\ phase\\‚\\Ä\\ù\\)\\ \ \(0\)\
\-\ prominent\\ thyroid\\ uptake\\,\\ also\\ salivary\\ glands\\ \ \(1\)\
\-\ often\\ can\\ see\\ focal\\ uptake\\ in\\ parathyroid\\ adenoma\ \(1\)\
\-\ delayed\\ images\\ \\ \\(\\‚\\Ä\\úparathyroid\\ phase\\‚\\Ä\\ù\\)\\ \\ \ \(0\)\
\-\ most\\ of\\ thyroid\\ uptake\\ has\\ washed\\ out\\ \ \(1\)\
\-\ a\\ focal\\ area\\ of\\ residual\\ activity\\ \\(adenoma\\)\\ or\\ multiple\\ foci\\ of\\ activity\\ \\(hyperplasia\\ or\\ multiple\\ adenomas\\)\\ will\\ be\\ seen\ \(1\)\
\-\ sensitivity\\ for\\ 300\\ mg\\ adenomas\\ is\\ approx\\ 85\\-90\\%\ \(0\)\
\-\ false\\ negative\\:\\ \\ small\\ size\\ and\\ lower\\ sensitivity\\ for\\ hyperplasia\\ \\(50\\-60\\%\\)\\.\ \(0\)\
\-\ false\\ positive\\:\\ \\ most\\ common\\ is\\ a\\ thyroid\\ adenoma\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ thyroid\\:\\ 0\\.4399458670798598\ \(0\)\
\-\ adenoma\\:\\ 0\\.3347333516949615\ \(0\)\
\-\ parathyroid\\:\\ 0\\.30718640358102156\ \(0\)\
\-\ pth\\:\\ 0\\.166126005003159\ \(0\)\
\-\ adenomas\\:\\ 0\\.16284989161218186\ \(0\)\
\-\ uptake\\:\\ 0\\.16142367713923395\ \(0\)\
\-\ sensitivity\\:\\ 0\\.142061941962273\ \(0\)\
\-\ accumulation\\:\\ 0\\.13522387420811502\ \(0\)\
\-\ images\\:\\ 0\\.12947532517079666\ \(0\)\
\-\ hyperplasia\\:\\ 0\\.1275923141780402\ \(0\)\
\-\ radiotracer\\:\\ 0\\.12216625085715081\ \(0\)\
\-\ phase\\:\\ 0\\.11975716782783308\ \(0\)\
\-\ focus\\:\\ 0\\.11855172650186302\ \(0\)\
\-\ extraglandular\\:\\ 0\\.1119078000274568\ \(0\)\
\-\ range\\:\\ 0\\.10860388094930194\ \(0\)\
\-\ lower\\:\\ 0\\.10727434054504441\ \(0\)\
\-\ thyroidal\\:\\ 0\\.10693387725117626\ \(0\)\
\-\ extrathyroidal\\:\\ 0\\.10693387725117626\ \(0\)\
\-\ washed\\:\\ 0\\.10340482287909503\ \(0\)\
\-\ activity\\:\\ 0\\.10275121353110951\ \(0\)\
\-\ early\\:\\ 0\\.10088263978503967\ \(0\)\
\-\ labs\\:\\ 0\\.09696084686883316\ \(0\)\
\-\ vit\\:\\ 0\\.09490184573073326\ \(0\)\
\-\ normalization\\:\\ 0\\.09490184573073326\ \(0\)\
\-\ normal\\:\\ 0\\.08571291643515974\ \(0\)\
\-\ region\\:\\ 0\\.08371366558004063\ \(0\)\
\-\ focal\\:\\ 0\\.08371366558004063\ \(0\)\
\-\ washout\\:\\ 0\\.0836615213481286\ \(0\)\
\-\ salivary\\:\\ 0\\.08249233202786369\ \(0\)\
\-\ 300\\:\\ 0\\.07998007740189161\ \(0\)\
\-\ approx\\:\\ 0\\.07998007740189161\ \(0\)\
\-\ increased\\:\\ 0\\.07568002395581698\ \(0\)\
\-\ exophytic\\:\\ 0\\.07515854419976682\ \(0\)\
\-\ confirmation\\:\\ 0\\.0748556349093912\ \(0\)\
\-\ glands\\:\\ 0\\.07427137196562573\ \(0\)\
\-\ or\\:\\ 0\\.07303082802522667\ \(0\)\
\-\ ensure\\:\\ 0\\.07292196865772915\ \(0\)\
\-\ most\\:\\ 0\\.07283587198906731\ \(0\)\
\-\ probable\\:\\ 0\\.07242119696552395\ \(0\)\
\-\ small\\:\\ 0\\.0721925628233325\ \(0\)\
\-\ etc\\:\\ 0\\.06883095940943176\ \(0\)\
\-\ of\\:\\ 0\\.06847054384527032\ \(0\)\
\-\ multiple\\:\\ 0\\.06845414546726927\ \(0\)\
\-\ surgical\\:\\ 0\\.06802180994662554\ \(0\)\
\-\ stones\\:\\ 0\\.06605704820485594\ \(0\)\
\-\ 56\\:\\ 0\\.06534776379342891\ \(0\)\
\-\ residual\\:\\ 0\\.06367529696888495\ \(0\)\
\-\ appropriate\\:\\ 0\\.061478875973223636\ \(0\)\
\-\ mg\\:\\ 0\\.061083125428575406\ \(0\)\
\-\ evident\\:\\ 0\\.06014624259680373\ \(0\)\
\-\ pending\\:\\ 0\\.05755407105649417\ \(0\)\
\-\ foci\\:\\ 0\\.05719430324965811\ \(0\)\
\-\ recurrent\\:\\ 0\\.056109202652294854\ \(0\)\
\-\ excision\\:\\ 0\\.055172319820523175\ \(0\)\
\-\ delayed\\:\\ 0\\.05475844721400675\ \(0\)\
\-\ at\\:\\ 0\\.05286208721823484\ \(0\)\
\-\ malignancy\\:\\ 0\\.05238695998892439\ \(0\)\
\-\ appears\\:\\ 0\\.05124393605994748\ \(0\)\
\-\ kidney\\:\\ 0\\.049161114403134636\ \(0\)\
\-\ now\\:\\ 0\\.04803553886832686\ \(0\)\
\-\ left\\:\\ 0\\.04774108150977426\ \(0\)\
\-\ elevated\\:\\ 0\\.04770397265827696\ \(0\)\
\-\ less\\:\\ 0\\.04760622550393308\ \(0\)\
\-\ size\\:\\ 0\\.047381132895662266\ \(0\)\
\-\ positive\\:\\ 0\\.046110978371988645\ \(0\)\
\-\ out\\:\\ 0\\.04599659802850273\ \(0\)\
\-\ area\\:\\ 0\\.045331846533011394\ \(0\)\
\-\ will\\:\\ 0\\.04503880494899817\ \(0\)\
\-\ see\\:\\ 0\\.043529756026171235\ \(0\)\
\-\ negative\\:\\ 0\\.04332202796434644\ \(0\)\
\-\ for\\:\\ 0\\.04241873425780254\ \(0\)\
\-\ the\\:\\ 0\\.041888595352751516\ \(0\)\
\-\ likely\\:\\ 0\\.041816280016016005\ \(0\)\
\-\ lymphoma\\:\\ 0\\.04167539180495899\ \(0\)\
\-\ common\\:\\ 0\\.039684741241073955\ \(0\)\
\-\ more\\:\\ 0\\.03842463196752903\ \(0\)\
\-\ is\\:\\ 0\\.03832712873019899\ \(0\)\
\-\ can\\:\\ 0\\.03672149711960031\ \(0\)\
\-\ seen\\:\\ 0\\.03294441159356267\ \(0\)\
\-\ also\\:\\ 0\\.032914982064138544\ \(0\)\
\-\ has\\:\\ 0\\.031963266985155746\ \(0\)\
\-\ which\\:\\ 0\\.03181905132901998\ \(0\)\
\-\ male\\:\\ 0\\.03115626937699309\ \(0\)\
\-\ and\\:\\ 0\\.028919610862656\ \(0\)\
\-\ be\\:\\ 0\\.028386704713722594\ \(0\)\
\-\ with\\:\\ 0\\.027404581991560897\ \(0\)\
\-\ an\\:\\ 0\\.026758812805141884\ \(0\)\
\-\ to\\:\\ 0\\.01749400983694195\ \(0\)\
\-\ in\\:\\ 0\\.017407904356755863\ \(0\)\
